568,681 Shares in Plus Therapeutics, Inc. (NASDAQ:PSTV) Purchased by AIGH Capital Management LLC

AIGH Capital Management LLC acquired a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Plus Therapeutics Stock Performance

PSTV opened at $1.41 on Monday. The business has a 50 day moving average of $1.60 and a 200-day moving average of $1.81. Plus Therapeutics, Inc. has a 52 week low of $0.97 and a 52 week high of $3.21.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share (EPS) for the quarter. Plus Therapeutics had a negative net margin of 240.15% and a negative return on equity of 805.57%. The business had revenue of $1.28 million for the quarter. As a group, analysts expect that Plus Therapeutics, Inc. will post -2.22 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Ascendiant Capital Markets decreased their target price on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Plus Therapeutics in a report on Friday, August 16th.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.